SSOAR Logo
    • Deutsch
    • English
  • English 
    • Deutsch
    • English
  • Login
SSOAR ▼
  • Home
  • About SSOAR
  • Guidelines
  • Publishing in SSOAR
  • Cooperating with SSOAR
    • Cooperation models
    • Delivery routes and formats
    • Projects
  • Cooperation partners
    • Information about cooperation partners
  • Information
    • Possibilities of taking the Green Road
    • Grant of Licences
    • Download additional information
  • Operational concept
Browse and search Add new document OAI-PMH interface
JavaScript is disabled for your browser. Some features of this site may not work without it.

Download PDF
Download full text

(302.0Kb)

Citation Suggestion

Please use the following Persistent Identifier (PID) to cite this document:
https://nbn-resolving.org/urn:nbn:de:0168-ssoar-202985

Exports for your reference manager

Bibtex export
Endnote export

Display Statistics
Share
  • Share via E-Mail E-Mail
  • Share via Facebook Facebook
  • Share via Bluesky Bluesky
  • Share via Reddit reddit
  • Share via Linkedin LinkedIn
  • Share via XING XING

Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants

[journal article]

Buitelaar, Jan
Medori, Rossella

Abstract

Attention-deficit/ hyperactivity disorder (ADHD), one of the most common neuropsychiatric conditions of childhood, often has a chronic course and persists into adulthood in many individuals. ADHD may have a clinically important impact on health-related quality of life in children, a significant impa... view more

Attention-deficit/ hyperactivity disorder (ADHD), one of the most common neuropsychiatric conditions of childhood, often has a chronic course and persists into adulthood in many individuals. ADHD may have a clinically important impact on health-related quality of life in children, a significant impact on parents' emotional health and interfere with family activities/ cohesion. To date, the main targets of ADHD treatment have focused on reducing the severity of symptoms during the school day and improving academic performance. However, the treatment of ADHD should reach beyond symptom control to address the issues of social competencies and improvement of health-related quality of life from the perspectives of individuals with ADHD and their families, to support them in reaching their full developmental potential. Methylphenidate (MPH) is recognised as the first-line choice of pharmacotherapy for ADHD in children and adolescents. This paper focuses on the importance and benefits to child development of ADHD symptom control beyond the school day only, i.e. extending into late afternoon and evening and uses the example of an extended-release MPH formulation (OROS® MPH) to demonstrate the potential benefits of active full day coverage (12 h) with a single daily dose. Concerns of long-term stimulant treatment are also discussed.... view less

Classification
Psychological Disorders, Mental Health Treatment and Prevention

Free Keywords
ADHD; Children; Quality of life; Methylphenidate; OROS

Document language
English

Publication Year
2009

Page/Pages
p. 325-340

Journal
European Child & Adolescent Psychiatry, 19 (2009) 4

DOI
https://doi.org/10.1007/s00787-009-0056-1

Status
Postprint; peer reviewed

Licence
PEER Licence Agreement (applicable only to documents from PEER project)


GESIS LogoDFG LogoOpen Access Logo
Home  |  Legal notices  |  Operational concept  |  Privacy policy
© 2007 - 2025 Social Science Open Access Repository (SSOAR).
Based on DSpace, Copyright (c) 2002-2022, DuraSpace. All rights reserved.
 

 


GESIS LogoDFG LogoOpen Access Logo
Home  |  Legal notices  |  Operational concept  |  Privacy policy
© 2007 - 2025 Social Science Open Access Repository (SSOAR).
Based on DSpace, Copyright (c) 2002-2022, DuraSpace. All rights reserved.